Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Xuefu Zhuyu Decoction Ameliorates Neuroinflammation after Traumatic Brain Injury via tRF-3-Leu-AAG/Gpr17 axis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Zhaoyu, Yuan Zhiqiang, Hou Jiaqi, Long Yali, Luo Ming, Lai Zili, Zhong Zixuan, Fan Xudong, Chen Daiyi, Tang Tao, Wang Yang
Аннотация
BACKGROUND: Xuefu Zhuyu Decoction (XFZYD) is clinically applied to traumatic brain injury (TBI) based on its traditional function of activating blood circulation and eliminating stasis. However, its precise mechanism underlying its efficacy, particularly through epigenetic regulation, are poorly understood.
AIM OF THE STUDY: We hypothesized that the neuroprotective effects of XFZYD post-TBI are mediated through the modulation of transfer RNA-derived small RNAs (tsRNAs), a key class of epigenetic regulators. This study aimed to delineate the specific tsRNA-dependent molecular pathway underlying XFZYD's ability to mitigate neuroinflammation and facilitate neurological recovery.
MATERIALS AND METHODS: We employed a murine TBI model treated with XFZYD. Following comprehensive assessment of neurological, histopathological, and inflammatory outcomes to test the mice behavior. The anti-infammatory roles of tRF-3-Leu-AAG was investigated in vivo and in vitro. RNA sequencing and bioinformatics analysis revealed G protein-coupled receptor 17 (Gpr17) is tRF-3-Leu-AAG's target. The direct interaction between tRF-3-Leu-AAG and Gpr17 is validated by dual-luciferase assay. Finally, in vitro rescue experiments conclusively established the tRF-3-Leu-AAG/Gpr17 axis as the functional pathway underlying XFZYD's effects.
RESULTS: XFZYD administration significantly attenuated neurological deficits, neuronal loss, and rescued cognitive impairment post-TBI. tRF-3-Leu-AAG, as a crucial mediator, which is suppressed by TBI and upregulated by XFZYD. The study demonstrated that tRF-3-Leu-AAG affect the inflammatory response. Critically, the anti-inflammatory and neuroprotective effects of XFZYD were entirely dependent on tRF-3-Leu-AAG. We further delineated the downstream signaling by identifying Gpr17 as a direct and functional target of tRF-3-Leu-AAG. XFZYD mediated tRF-3-Leu-AAG binds to the 3'UTR of Gpr17 mRNA to suppress its expression, thereby inhibiting the Gpr17-induced pro-inflammatory pathway.
CONCLUSION: This study elucidates that XFZYD exerts neuroprotection and anti-inflammation after TBI through tRF-3-Leu-AAG/Gpr17 axis. Our findings provide a modern scientific rationale for the application of XFZYD in treating TBI.
AIM OF THE STUDY: We hypothesized that the neuroprotective effects of XFZYD post-TBI are mediated through the modulation of transfer RNA-derived small RNAs (tsRNAs), a key class of epigenetic regulators. This study aimed to delineate the specific tsRNA-dependent molecular pathway underlying XFZYD's ability to mitigate neuroinflammation and facilitate neurological recovery.
MATERIALS AND METHODS: We employed a murine TBI model treated with XFZYD. Following comprehensive assessment of neurological, histopathological, and inflammatory outcomes to test the mice behavior. The anti-infammatory roles of tRF-3-Leu-AAG was investigated in vivo and in vitro. RNA sequencing and bioinformatics analysis revealed G protein-coupled receptor 17 (Gpr17) is tRF-3-Leu-AAG's target. The direct interaction between tRF-3-Leu-AAG and Gpr17 is validated by dual-luciferase assay. Finally, in vitro rescue experiments conclusively established the tRF-3-Leu-AAG/Gpr17 axis as the functional pathway underlying XFZYD's effects.
RESULTS: XFZYD administration significantly attenuated neurological deficits, neuronal loss, and rescued cognitive impairment post-TBI. tRF-3-Leu-AAG, as a crucial mediator, which is suppressed by TBI and upregulated by XFZYD. The study demonstrated that tRF-3-Leu-AAG affect the inflammatory response. Critically, the anti-inflammatory and neuroprotective effects of XFZYD were entirely dependent on tRF-3-Leu-AAG. We further delineated the downstream signaling by identifying Gpr17 as a direct and functional target of tRF-3-Leu-AAG. XFZYD mediated tRF-3-Leu-AAG binds to the 3'UTR of Gpr17 mRNA to suppress its expression, thereby inhibiting the Gpr17-induced pro-inflammatory pathway.
CONCLUSION: This study elucidates that XFZYD exerts neuroprotection and anti-inflammation after TBI through tRF-3-Leu-AAG/Gpr17 axis. Our findings provide a modern scientific rationale for the application of XFZYD in treating TBI.